The infection is caused by exposure to mucor mould and it affects the sinuses, the brain and the lungs and can be life-threatening.
“A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from mucormycosis, a post-Covid complication,” the ministry said in a statement.
The government is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra imports of this drug and increase in its production domestically, it added.
“After reviewing the stock position with the manufacturers/importers, and the demand pattern of Amphotericin B, the Department of Pharma, has on 11th May, 2021, allocated this drug amongst the States/UTs based on expected supply that will be available from May 10 to May 31, 2021,” the statement said.
States have been requested to put in place a mechanism for equitable distribution of supplies amongst government and private hospitals and health care agencies, it added.
States have also been requested to publicise in the state the ‘Point of Contact’ for private and government hospitals to obtain the drug from this allocation, the statement said.
“The arrangements for supply will be monitored by the National Pharmaceuticals Pricing Authority (NPPA),” it added.